Search
01/02/2024
Current management of atrial fibrillation in routine practice according to the last ESC guidelines: an EHRA physician survey-how are we dealing with controversial approaches?
Guerra, JM, Weidmann, ZM, Perrotta, L, Sultan, A, Anic, A, Metzner, A, Providencia, R, Boveda, S, Chun, J. Current management of atrial fibrillation in routine practice according to the last ESC guidelines: an EHRA physician survey-how are we dealing with controversial approaches?. EUROPACE. 2024; 26(2)DOI:10.1093/europace/euae012. PMID:38227804. IF:7.400(Q1/2D).
01/02/2024
Cross-Validation of Risk Scores for Patients Undergoing Transcatheter Edge-to-Edge Repair for Mitral Regurgitation.
Estévez-Loureiro R, Shah N, Raposeiras-Roubin S, Kotinkaduwa LN, Madhavan MV, Gray WA, Lindenfeld J, Adamo M, Abraham WT, Freixa X, Grayburn PA, Arzamendi D, Kar S, Benito-González T, Lim DS, Montefusco A, Redfors B, Pascual I, Nombela-Franco L, Rodés-Cabau J, Shuvy M, Moñivas V, Godino C, Mack MJ, Bedogni F, Stone GW. Cross-Validation of Risk Scores for Patients Undergoing Transcatheter Edge-to-Edge Repair for Mitral Regurgitation.. Journal Of The Society For Cardiovascular Angiography & Interventions. 2024; 3(2)DOI:10.1016/j.jscai.2023.101227. PMID:39132211. IF:(Q/D).
01/02/2024
Adult transition program led by clinical nurse specialist: The case of congenital coagulopathies
Benedicto, C, Caballero, N, Rambla, M, Macho, R, Burriel, C, Berrueco, R, Vilalta, N, Carrasco, M, Mateo, J, Triquell, M. Adult transition program led by clinical nurse specialist: The case of congenital coagulopathies. HAEMOPHILIA. 2024; 30DOI:. PMID:. IF:3.000(Q2/4D).
01/02/2024
The BRAFV600E mutation maintains the aggressiveness of papillary thyroid cancers requiring downregulation of primary cilia
Ma, CX, Ma, XN, Liu, JJ, Guan, CH, Li, YD, Zhao, N, Mauricio, D, Fu, SB. The BRAFV600E mutation maintains the aggressiveness of papillary thyroid cancers requiring downregulation of primary cilia. MOLECULAR AND CELLULAR ENDOCRINOLOGY. 2024; 581DOI:10.1016/j.mce.2023.112113. PMID:37989409. IF:3.600(Q2/4D).
01/02/2024
A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting
Beato-Víbora, PI, Chico, A, Moreno-Fernandez, J, Bellido-Castañeda, V, Nattero-Chávez, L, Picón-César, MJ, Martínez-Brocca, MA, Giménez-Alvarez, M, Aguilera-Hurtado, E, Climent-Biescas, E, Azriel-Mir, S, Rebollo-Román, A, Yoldi-Vergara, C, Pazos-Couselo, M, Alonso-Carril, N, Quirós, C. A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting. DIABETES CARE. 2024; 47(2)DOI:10.2337/dc23-1355. PMID:37948469. IF:16.600(Q1/1D).
01/02/2024
Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data
Villanueva, C, Sapena, V, Lo, GH, Seo, YS, Shah, HA, Singh, V, Tripathi, D, Schepke, M, Gheorghe, C, Bonilha, DQ, Jutabha, R, Wang, HM, Rodrigues, SG, Brujats, A, Lee, HA, Azam, Z, Kumar, P, Hayes, PC, Sauerbruch, T, Chen, WC, Iacob, S, Libera, ED, Jensen, DM, Alvarado, E, Torres, F, Bosch, J. Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2024; 59(3)DOI:10.1111/apt.17824. PMID:38108646. IF:6.700(Q1/1D).